yeahright
Well-known member
Cortex AMPAKINE(R) Drugs Can Reverse Age Related Memory Decline in an Animal Model-University of California, Irvine investigators demonstrate how AMPAKINE drugs boost the brain's own protein for fighting age-related deficits in memory mechanism
Business Wire
08-04-06
IRVINE, Calif., Aug 02, 2006 (BUSINESS WIRE) -- In the August 2006 issue of The Journal of Neurophysiology, Drs. Christine Gall and Gary Lynch and their research staff reported that it was possible to use AMPAKINE compounds to reverse age-related declines in cognitive functions in old rats, returning their cognitive ability to that seen in young rats. The authors attributed this effect to the ability of AMPAKINE drugs to increase endogenous brain-derived neurotrophic factor (BDNF) in the neurons in the brains of older rats. The study used two of Cortex Pharmaceuticals' (AMEX: COR) high impact AMPAKINE drugs that are in preclinical development testing at the company. When an antagonist to BDNF was co-administered with the AMPAKINE compounds, the older rats returned to age-related cognitive impairment level.
Dr. Gall said, "This is a significant discovery because these results indicate the exciting possibility that AMPAKINE compounds could be used to treat learning and memory loss associated with normal aging."
Cortex is developing both high and low impact AMPAKINE drugs that bind at different sites on the AMPA-receptor of neurons. The high impact compounds under development are orally active and therefore the up-regulation of BDNF with these drugs is a significant finding not only for restoring memory declines as a result of aging, but also for other neurodegenerative diseases such as Huntington's Disease, Fragile X, Parkinson's and Alzheimer's disease, where elevation of BDNF may produce disease modifying effects in the patient populations.
The article by Drs. Gall and Lynch can be found by accessing the following website link: Invalid Link Removed
Business Wire
08-04-06
IRVINE, Calif., Aug 02, 2006 (BUSINESS WIRE) -- In the August 2006 issue of The Journal of Neurophysiology, Drs. Christine Gall and Gary Lynch and their research staff reported that it was possible to use AMPAKINE compounds to reverse age-related declines in cognitive functions in old rats, returning their cognitive ability to that seen in young rats. The authors attributed this effect to the ability of AMPAKINE drugs to increase endogenous brain-derived neurotrophic factor (BDNF) in the neurons in the brains of older rats. The study used two of Cortex Pharmaceuticals' (AMEX: COR) high impact AMPAKINE drugs that are in preclinical development testing at the company. When an antagonist to BDNF was co-administered with the AMPAKINE compounds, the older rats returned to age-related cognitive impairment level.
Dr. Gall said, "This is a significant discovery because these results indicate the exciting possibility that AMPAKINE compounds could be used to treat learning and memory loss associated with normal aging."
Cortex is developing both high and low impact AMPAKINE drugs that bind at different sites on the AMPA-receptor of neurons. The high impact compounds under development are orally active and therefore the up-regulation of BDNF with these drugs is a significant finding not only for restoring memory declines as a result of aging, but also for other neurodegenerative diseases such as Huntington's Disease, Fragile X, Parkinson's and Alzheimer's disease, where elevation of BDNF may produce disease modifying effects in the patient populations.
The article by Drs. Gall and Lynch can be found by accessing the following website link: Invalid Link Removed
